Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00372853 · ClinicalTrials.gov registry record · Phase 1
Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT00372853 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 28 participants.
The verdict
NCT00372853, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.
Interventions
- DRUG SU011248
- DRUG CP-675,206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2006-11 |
| Est. Completion | 2010-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00372853
The ClinicalTrials.gov registry entry for NCT00372853 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SU011248 is the first listed.
NCT00372853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00372853 about?
NCT00372853 is a clinical study titled "Dose-Finding Study Of CP-675,206 And SU011248 In Patients With Metastatic Renal Cell Carcinoma". This study will determine the highest tolerable dose of CP-675,206 when given in combination with SU011248.
What is the current status of trial NCT00372853?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2006-11. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00372853?
The interventions under investigation include: SU011248 (DRUG), CP-675,206 (DRUG).
Who is sponsoring clinical trial NCT00372853?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.